{"schema_version":"1.0","type":"article","title":"默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近","url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.md","lang":"zh-Hant","date":"2026-06-21","publish_at":"2026-06-21T08:00:00+08:00","updated_at":"2026-06-21","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"在全球腫瘤藥市場裡，很少有一家公司比 Merck（默沙東）更懂 PD-1。","key_points":[],"facts":[],"sections":["01｜Merck 為什麼突然更重視 MK-2010？","02｜HARMONi-6 為什麼讓大藥廠開始認真看 PD-1／VEGF？","03｜MK-2010 現在的資料：看得到潛力，但還不到驚艷","04｜Merck 真正想做的，不一定是複製 HARMONi-6","05｜sac-TMT 與 MK-2010：Merck 可能正在構築新的「後 Keytruda 組合包」","06｜Kelun-Biotech 引進 CR-001，可能也在提醒 Merck：組合戰才剛開始","07｜Merck 的矛盾：既要保護 Keytruda，也不能錯過下一代免疫主軸","結語｜Merck 沒有失去王冠，但它已經開始看見新的王座形狀"],"references":[{"title":"[Merck product pipeline]","source":"","date":"","url":"https://www.merck.com/research/product-pipeline/"},{"title":"[Merck Keytruda prescribing information]","source":"","date":"","url":"https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf"},{"title":"[Summit Therapeutics: ivonescimab clinical development]","source":"","date":"","url":"https://www.smmttx.com/"},{"title":"各公司官網與公開資料","source":"","date":"","url":""}],"images":[{"alt":"Facebook 原圖：默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 1）","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-01.png"},{"alt":"Facebook 原圖：默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 2）","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-02.png"},{"alt":"Facebook 原圖：默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 3）","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-03.png"},{"alt":"Facebook 原圖：默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 4）","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/cover-generated.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-21）。默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近。https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}